Drugs / Azenosertib
Trials 17
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 zentalis.com ↗
Activity of the combined regimen across all dose cohorts achieved 39% ORR and 7.3-month median PFS |
| 2026-04-17 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 zentalis.com ↗
The data show encouraging preclinical activity of azenosertib in triple-negative breast cancer (TNBC) and highlight the poor prognosis of Cyclin E1-positive ovarian cancer patients with currently available treatments in a real-world data analysis. |
| 2026-04-09 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer zentalis.com ↗
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups |
| 2025-03-15 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals Presents Updated Clinical Data At The Society Of Gynecologic Oncology 2025 Annual Meeting On Women’s Cancer zentalis.com ↗
In the intent-to-treat patients with Cyclin E1+ PROC (patients who received at least one dose of azenosertib), the ORR was 31.3% (15/48; 95% CI: 18.7 - 46.3), and an mDOR of 6.3 months (95% CI: 2.7 – not estimable). |
| 2025-01-29 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity In Cyclin E1+, Platinum-Resistant Ovarian Cancer zentalis.com ↗ |
| 2025-01-09 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Regulatory Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation And Virtual Corporate Event To Present Updated Data From Azenosertib Clinical Studies zentalis.com ↗ |
| 2024-09-16 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Regulatory Zentalis Pharmaceuticals Announces Fda Has Lifted Partial Clinical Hold On Azenosertib Studies zentalis.com ↗
The FDA has cleared the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. |
| 2024-09-09 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals To Present Preclinical Azenosertib Data At ESMO 2024 zentalis.com ↗
Data in the abstract showed that the combination of azenosertib with TOP1 inhibitors demonstrated significant synergistic effects in all cell lines tested. |
| 2024-06-18 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Regulatory Zentalis Pharmaceuticals Provides Update On Azenosertib Clinical Development Program zentalis.com ↗ |
| 2024-05-23 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals To Present Promising Results From Phase 1 Trial Of Azenosertib And Gemcitabine In Relapsed Or Refractory Osteosarcoma At 2024 American Society Of Clinical Oncology Annual Meeting zentalis.com ↗
today announced the presentation of final results from a Phase 1 trial of azenosertib and gemcitabine in relapsed or refractory (R/R) osteosarcoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. |
| 2024-04-02 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity With Kras(G12C) Inhibitors At AACR Annual Meeting 2024 zentalis.com ↗
Research demonstrated that the Company’s WEE1 inhibitor, azenosertib, exerts synergistic anti-tumor activity when combined with KRAS G12C inhibitors. |
| 2023-11-06 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results And Operational Updates zentalis.com ↗
Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients |
| 2021-11-17 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Regulatory Zentalis Pharmaceuticals Announces Fast Track Designation Granted By The U.S. Fda To Zn-C3 For The Treatment Of Uterine Serous Carcinoma zentalis.com ↗
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZN-c3, the Company’s oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma (USC) in adult women. |
| 2021-06-28 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On Zn-C3 (Wee1I) And Zn-C5 (Serd) And Two Potentially Registrational Trials For Zn-C3, With The First Trial Already Initiated zentalis.com ↗
Reports additional ZN-c3 Phase 1 interim monotherapy data, demonstrating increased tumor reduction and durability in the exceptional responder population, as well as newly confirmed responses and an additional unconfirmed PR in USC |
| 2021-04-10 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals Announces Promising Initial Data Presented In A Late-Breaking Session At Aacr On Zn-C3, Its Wee1 Inhibitor, In Patients With Advanced Solid Tumors zentalis.com ↗
Initial results showed that monotherapy ZN-c3 use resulted in Exceptional Responses in heavily pre-treated patients in a range of solid tumors, including Partial Responses (PRs) in ovarian cancer, colorectal cancer, non-small cell lung carcinoma and uterine serous carcinoma. |
| 2019-12-18 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Regulatory Zentalis Pharmaceuticals Announces Fda Clearance Of The Ind For Its Third Oncology Drug Candidate, Zn-C3, A Wee1 Inhibitor, And The Dosing Of The First Patient In A Phase 1/2 Clinical Trial zentalis.com ↗ |
All press releases naming this drug 32 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azenosertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04814108 ↗ |
| Known as | KP-2638 | “This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or...” NCT04814108 ↗ |
| Known as | ZN-c3 | “ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase)” NCT06015659 ↗ |
| Action | Inhibit | “inhibitor of WEE1” NCT05128825 ↗ |
| Modality | Small molecule | “a small molecule inhibitor of the WEE1 tyrosine kinase” NCT06015659 ↗ |
| Route | Oral | “Azenosertib (ZN-c3) taken orally with food” NCT04814108 ↗ |
| Target | WEE1 | “inhibitor of WEE1” NCT05128825 ↗ |